Grants and Contributions:

Back to search

Title:

Chemical biosensors for improving drug production

Agreement Number:

EGP

Agreement Value:

$25,000.00

Agreement Date:

Jan 10, 2018 -

Organization:

Natural Sciences and Engineering Research Council of Canada

Location:

Ontario, CA

Reference Number:

GC-2017-Q4-01223

Agreement Type:

Grant

Report Type:

Grants and Contributions

Additional Information:

Grant or Award spanning more than one fiscal year (2017-2018 to 2018-2019).

Recipient's Legal Name:

McMillen, David (University of Toronto)

Program:

Engage Grants for universities

Program Purpose:

Many pharmaceuticals are complex, natural compounds that can be difficult to extract from their sources or tox000D
synthesize chemically. To overcome this, some pharmaceuticals can be produced in a host organism that isx000D
easier to manage on a commercial scale. Hyasynth Bio has developed strains of yeast that producex000D
cannabinoids, a class of compounds with great potential as medicines and therapeutics. Early approvedx000D
cannabinoid medicines in Canada include nabiximols, for adjunctive analgesic treatment in adult patients withx000D
advanced cancer, and nabilone, for severe nausea and vomiting associated with cancer chemotherapy. Tox000D
rapidly screen yeast strains with improved cannabinoid production, a simple way of detecting and quantifyingx000D
these compounds is required. We aim to develop a new means of detecting medicinal cannabinoids to improvex000D
their commercial production.